Skip to main content
FRMSL logo

FRMSL — Investor Relations & Filings

Ticker · 4746 ISIN · TW0004746003 TW Manufacturing
Open in API
Filings indexed 1,872 across all filing types
Latest filing 2021-07-16 Remuneration Information
Country TW Taiwan
Listing TW 4746

About FRMSL

www.formosalab.com

Formosa Laboratories, Inc. is a Contract Development and Manufacturing Organization (CDMO) specializing in the development and production of Active Pharmaceutical Ingredients (APIs) and finished dosage forms. The company provides integrated services ranging from process development and custom synthesis to large-scale commercial manufacturing. Its core product portfolio includes UV-filters, Vitamin D derivatives, and polymers such as cholesterol and phosphate binders. Formosa Laboratories offers specialized expertise in Antibody-Drug Conjugates (ADCs) and injectable manufacturing, including cytotoxic and freeze-dried products. Maintaining high quality standards, its facilities are cGMP-compliant and have been successfully inspected by the US FDA, TFDA, EDQM, and PMDA. The company serves a global clientele, providing one-stop solutions for complex chemical synthesis, fermentation, and peptide production.

Recent filings

Filing Released Lang Actions
代重要子公司台新藥(股)公司公告第一屆薪資報酬委員會成員
Remuneration Information Classification · 95% confidence The document is a short announcement regarding the appointment of members to the first Compensation Committee of a subsidiary company. It includes details about the new members and the effective date. There is no financial data, no report attached or referenced, and no indication of a full report or detailed financial disclosure. The content relates to management or board committee changes, specifically about remuneration committee members, which aligns with Remuneration Information filings. The document length is short (737 characters), and it is a direct announcement of committee member appointments, not a report or presentation. Therefore, the best fitting category is Remuneration Information (DEF 14A).
2021-07-16 Chinese
代重要子公司台新藥(股)公司公告董事會通過選任董事長
Board/Management Information Classification · 100% confidence The document is a formal announcement from a listed company (4746 台耀) regarding a change in the company's board of directors, specifically the reappointment of the chairman. It includes details such as the date of the board resolution, names of the outgoing and incoming chairman, and the reason for the change. There is no financial data, report, or presentation content. This fits the category of Board/Management Information (MANG), which covers announcements of changes in the company's board or senior management.
2021-07-16 Chinese
110年7月變更登記
Share Issue/Capital Change Classification · 95% confidence The document contains detailed information about the company's capital structure, including authorized capital, paid-in capital, capital increases, and convertible bonds. It is a structured disclosure of share capital details rather than a narrative report or announcement. The document length is short (805 characters), but it is not merely an announcement or a certification. It provides specific data on share capital changes and related dates, which aligns with announcements regarding share capital changes. Therefore, the document is best classified as a Share Issue/Capital Change (SHA) filing.
2021-07-15 Chinese
代重要子公司台新藥(股)公司公告第一屆審計委員會成員
Board/Management Information Classification · 95% confidence The document is a short announcement (729 characters) about the appointment of new members to the audit committee of a subsidiary company. It includes details such as names, titles, and effective dates of the new appointees. There is no financial data, no report attached or referenced, and no indication of a full report or detailed financial statements. The content is about management/board changes specifically related to the audit committee members. Therefore, it fits best under Board/Management Information (MANG).
2021-07-09 Chinese
代重要子公司台新藥(股)公司公告股東會決議解除董事競業 禁止之限制
Board/Management Information Classification · 95% confidence The document is a formal announcement from a listed company (台耀) regarding a shareholder meeting resolution to lift restrictions on directors engaging in competitive business activities. It includes details such as the date of the shareholder meeting, names and titles of directors permitted to engage in competitive activities, the period of permission, and voting results. The content focuses on board/management decisions and shareholder meeting resolutions related to director activities, not financial results or audit information. The document length is short (979 characters) and it is a regulatory announcement of a board-related decision rather than a full report. Therefore, it fits best under Board/Management Information (MANG).
2021-07-09 Chinese
代重要子公司台新藥(股)公司公告法人董事指派代表人
Board/Management Information Classification · 95% confidence The document is a short announcement regarding a change in the appointment of a representative director for a subsidiary company. It includes details such as the date of change, the name of the new representative, and the reason for the change. There is no financial data, no mention of financial results, reports, or regulatory filings beyond this director appointment. This fits the category of Board/Management Information (MANG), which covers announcements of changes in the company's board of directors or senior management.
2021-07-09 Chinese

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.